Vir Biotechnology utilizes its PRO-XTEN masking technology and proprietary dAIsY AI platform to design dual-masked T-cell engager candidates against solid tumors

From the articleVir makes solid tumor T cell engager deal with GileadAlso in Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal | Reuters